Acute Decompensated Heart Failure
Pipeline by Development Stage
Drug Modality Breakdown
Cardiovascular is a $69.4B mature market dominated by anticoagulants and metabolic therapies with stable blockbuster portfolios.
Key Trends
- FXa inhibitors (ELIQUIS, XARELTO) command 62% of market spending, creating limited room for new entrants
- SGLT2 inhibitors gaining traction in heart failure indication, signaling expansion beyond traditional anticoagulation
- Multiple patent cliffs (JANUVIA 2027, OPSUMIT 2029) create near-term revenue vulnerability but reinvestment pressure
Career Verdict
Strong choice for commercial, clinical operations, and device integration roles; limited opportunity for innovative pipeline development given market maturity.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (Apixaban) | Bristol Myers Squibb | $18.3B | 26% | Peak | Stable | 15.0yr |
| 2 | JARDIANCE (Empagliflozin) | Boehringer Ingelheim | $8.8B | 13% | Peak | Growing | 8.6yr |
| 3 | XARELTO (Rivaroxaban) | Johnson & Johnson | $6.3B | 9% | Peak | Stable | |
| 4 | FARXIGA (Dapagliflozin) | AstraZeneca | $4.3B | 6% | Peak | Growing | 15.4yr |
| 5 | JANUVIA (Sitagliptin) | Merck & Co. | $4.1B | 6% | LOE_Approaching | Declining | 1.1yr |
Drug Class Breakdown
Mature, stable revenue base
Growing in heart failure and renal indications
Declining as LOE approaches 2027
Stable in heart failure management
Niche pulmonary hypertension market
Career Outlook
StableCardiovascular careers are stable but not expanding; the market is mature, dominated by blockbuster franchises with predictable commercial cycles and patent cliffs. Professionals entering this space should expect strong compensation (Commercial $210K avg, Medical Affairs $201K avg) but limited opportunity to drive breakthrough innovation. Device company roles offer better growth trajectories than pharma, particularly in remote monitoring, diagnostics, and patient engagement technologies.
Breaking In
Target device companies (Abbott, Medtronic) for growth potential; if joining pharma, focus on Commercial or Clinical Operations roles where hiring is active and compensation is competitive.
For Experienced Professionals
Leverage cardiovascular expertise to move into medical device strategy, digital health partnerships, or adjacent therapeutic areas; R&D opportunity is limited and may require lateral moves to access innovation-focused roles.
In-Demand Skills
Best For
Hiring Landscape
Cardiovascular hiring is concentrated in device companies (Abbott 337, Medtronic 317) rather than pharma, reflecting the therapeutic area's reliance on hardware solutions and patient management infrastructure. Pharma hiring (Johnson & Johnson 261, Bristol Myers Squibb 52) is heavily weighted toward Commercial (468 roles) and Clinical Operations (296 roles), with minimal R&D investment (14 roles). Medical device integration and remote patient monitoring expertise are increasingly valued as the market consolidates.
Top Hiring Companies
By Department
Device companies offer more growth opportunities; pharma roles are high-paying but oriented toward mature market execution rather than innovation.
On Market (1)
Approved therapies currently available
Competitive Landscape
16 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 19 trials with date data
Clinical Trials (19)
Total enrollment: 3,536 patients across 19 trials
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
Evaluate the Efficacy and Safety of Short-term Administration of SIMDAX
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure
Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure
Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure
A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure
DORAYA-HF OUS Assessment of the Doraya Catheter for the Treatment of ADHF Patients With Insufficient Response to Diuretics
EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU)
Reprieve System Pilot Study
A Study to Assess Multidomain Endpoints of an ECG Patch
DORAYA-HF Early Feasibility Study
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)
Evaluation of Blood Volume Analysis- Guided Management of Decompensated Heart Failure
A Feasibility Study on Ultrafiltration and Blood Volume Measurements
A Study to Evaluate Lung Ultrasound as a Method to Measure Changes in Extravascular Lung Water Induced by Positional Changes (LUPE)
Cardiovascular Improvements With MV ASV Therapy in Heart Failure
Gas Exchange for Predicting Hospital Heart Failure Readmissions
Adaptive Servo Ventilation (ASV) in Heart Failure
REducing 30-day ADMIssions in posT-discharge Subjects (READMIT)
Related Jobs in Cardiovascular
Senior Manufacturing Engineer
Staff Product Development Engineer
Application Security Engineer
Senior Software Engineer
Staff Software Engineer
Director, Clinical Quality Lead
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.